Antimicrobial Peptides Are Elevated in COVID-19 Patients and May Drive Kidney Damage | Research

The takeaway

COVID-19 patients had elevated levels of α-defensin 1, α-defensin 3, and β-defensin 3 antimicrobial peptides, with α-defensins significantly higher in those who developed acute kidney injury.

AUC 0.86-0.88
IL-10 markers for predicting acute kidney injury in COVID-19 patients

What the researchers found

α-defensin 1 and α-defensin 3 were significantly elevated in COVID-19 patients with AKI vs without AKI, and IL-10/IL-10×IL-1B showed excellent AKI discrimination (AUC 0.86-0.88).

Why it matters

Understanding the role of antimicrobial peptides in COVID-19 organ damage could reveal new biomarkers for early kidney injury detection and potential therapeutic targets to prevent AKI in severe infections.

The numbers in context

Five AMPs measured: LL-37, α-defensin 1, α-defensin 3, β-defensin 1, and β-defensin 2. Over 300 AMPs described in mammals total.

How the study worked

Cross-sectional observational study measuring five AMPs (ELISA) and six cytokines (Milliplex bead immunoassay) in three groups: 15 healthy controls, 36 COVID-19 without AKI, and 17 COVID-19 with AKI.

Who was studied

COVID-19 patients with acute kidney injury

What this study cannot tell us

Small sample sizes (especially AKI group, n=17); cross-sectional design cannot establish causality; single-center study; COVID-19 severity differences between groups may confound AMP comparisons; no longitudinal tracking of AMP levels.

How to read the evidence

Preliminary evidence from a small cross-sectional study. Novel findings about AMP elevation in COVID-19 AKI, but sample sizes are too small for definitive conclusions.

When this study was published

Published in 2024, contributing to the evolving understanding of COVID-19 pathophysiology and organ damage mechanisms.

The bigger picture

Antimicrobial peptides are increasingly recognized as double-edged swords — protective against infection but potentially harmful when overproduced during severe inflammatory responses. This study adds evidence that AMPs may contribute to organ damage in severe COVID-19.

Questions still open

Do elevated α-defensins cause kidney injury or simply reflect it?
Could blocking α-defensin activity prevent COVID-19-associated AKI?
Are these AMP patterns specific to COVID-19 or common to other severe infections?

Common questions

What are antimicrobial peptides and why are they relevant to COVID-19?

Antimicrobial peptides (AMPs) like defensins are small immune proteins that normally fight infections. In COVID-19, some AMPs become overly elevated and may actually contribute to organ damage — particularly kidney injury — as part of the excessive immune response.

Could measuring defensin levels help predict kidney problems in COVID-19 patients?

Possibly. This study found α-defensin 1 and 3 were significantly higher in COVID-19 patients who developed kidney injury. Combined with IL-10 markers (which showed 86-88% accuracy), these could potentially help identify at-risk patients early.

Read the original research

Antimicrobial peptides and other potential biomarkers of critical illness in SARS-CoV-2 patients with acute kidney injury. AMPAKI-CoV study.

Physiological reports, 12(3), e15945

View on PubMed ↗Publisher’s paper ↗

Citation

Theotonio Dos Santos, Lucas Ferreira; Barbeiro, Hermes Vieira; Barbeiro, Denise Frediani; de Souza, Heraldo Possolo; Pinheiro da Silva, Fabiano. (2024). Antimicrobial peptides and other potential biomarkers of critical illness in SARS-CoV-2 patients with acute kidney injury. AMPAKI-CoV study.. Physiological reports, 12(3), e15945. https://doi.org/10.14814/phy2.15945